- Home
- NCDL vs ELVN Comparison
NCDL vs ELVN Comparison
Compare NCDL & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCDL
- ELVN
- Stock Information
- Founded
- NCDL 2019
- ELVN 2016
- Country
- NCDL United States
- ELVN United States
- Employees
- NCDL N/A
- ELVN N/A
- Industry
- NCDL
- ELVN Biotechnology: Pharmaceutical Preparations
- Sector
- NCDL
- ELVN Health Care
- Exchange
- NCDL NYSE
- ELVN Nasdaq
- Market Cap
- NCDL 919.2M
- ELVN 1.1B
- IPO Year
- NCDL N/A
- ELVN 2020
- Fundamental
- Price
- NCDL $17.71
- ELVN $21.80
- Analyst Decision
- NCDL Buy
- ELVN Strong Buy
- Analyst Count
- NCDL 6
- ELVN 5
- Target Price
- NCDL $18.33
- ELVN $37.80
- AVG Volume (30 Days)
- NCDL 222.2K
- ELVN 227.8K
- Earning Date
- NCDL 02-27-2025
- ELVN 03-13-2025
- Dividend Yield
- NCDL 9.89%
- ELVN N/A
- EPS Growth
- NCDL N/A
- ELVN N/A
- EPS
- NCDL N/A
- ELVN N/A
- Revenue
- NCDL N/A
- ELVN N/A
- Revenue This Year
- NCDL N/A
- ELVN N/A
- Revenue Next Year
- NCDL N/A
- ELVN N/A
- P/E Ratio
- NCDL N/A
- ELVN N/A
- Revenue Growth
- NCDL N/A
- ELVN N/A
- 52 Week Low
- NCDL $16.00
- ELVN $10.90
- 52 Week High
- NCDL $18.10
- ELVN $30.03
- Technical
- Relative Strength Index (RSI)
- NCDL 66.29
- ELVN 48.03
- Support Level
- NCDL $17.42
- ELVN $21.16
- Resistance Level
- NCDL $17.45
- ELVN $22.91
- Average True Range (ATR)
- NCDL 0.17
- ELVN 1.00
- MACD
- NCDL 0.04
- ELVN 0.06
- Stochastic Oscillator
- NCDL 77.92
- ELVN 45.02
About NCDL NUVEEN CHURCHILL DIRECT LENDNG CORP
Nuveen Churchill Direct Lending Corp is a specialty finance company focused predominantly on investing in senior secured loans to private equity-owned U.S. middle market companies. It invest in senior secured loans that typically pay floating interest rates and are senior in the capital structure to junior debt and equity.
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage precision oncology company focused on the discovery and development of potentially first-in-class precision oncology therapies. Enliven's programs are designed to address issues such as tolerability, combinability, resistance and disease escape through brain metastases. Its product candidates include ELVN-001 which is a potent, selective, small molecule kinase inhibitor designed to specifically target the BCR-ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia, and the ELVN-002 which is central nervous system (CNS) penetrant and irreversible HER2 inhibitor with activity against wild type HER2 and various HER2 mutations.